Retrochorionic hematoma in congenital afibrinogenemia: Resolution with fibrinogen concentrate infusions

Without treatment, pregnancies in patients with congenital afibrinogenemia terminate in miscarriage at 5–6 weeks of gestation. Animal model studies have suggested that implantation site bleeding contributes to miscarriage in afibrinogenemia; however, retrochorionic hematoma in human congenital afibr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hematology 2007-04, Vol.82 (4), p.317-320
Hauptverfasser: Aygören‐Pürsün, E., Martinez Saguer, I., Rusicke, E., Louwen, F., Geka, F., Ivaskevicius, V., Oldenburg, J., Klingebiel, T., Kreuz, W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Without treatment, pregnancies in patients with congenital afibrinogenemia terminate in miscarriage at 5–6 weeks of gestation. Animal model studies have suggested that implantation site bleeding contributes to miscarriage in afibrinogenemia; however, retrochorionic hematoma in human congenital afibrinogenemia has not been previously observed. A patient with congenital afibrinogenemia receiving fibrinogen prophylaxis developed a retrochorionic hematoma in the first trimester. With continuous intensified fibrinogen concentrate replacement the hematoma resolved over 6 weeks, and the patient delivered a healthy infant. Median fibrinogen levels in the first trimester were 48 mg/dL and in second and third trimester 44 mg/dL. Median fibrinogen levels under 60 mg/dL may be adequate to maintain pregnancy in patients with congenital afibrinogenemia, although it is possible that higher levels might reduce the risk of hemorrhagic events. Am. J. Hematol., 2006. © 2006 Wiley‐Liss, Inc.
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.20802